恶二唑类抗菌药物的构效关系
Structure-Activity Relationship for the Oxadiazole Class of Antibacterials.
作者信息
Boudreau Marc A, Ding Derong, Meisel Jayda E, Janardhanan Jeshina, Spink Edward, Peng Zhihong, Qian Yuanyuan, Yamaguchi Takao, Testero Sebastian A, O'Daniel Peter I, Leemans Erika, Lastochkin Elena, Song Wei, Schroeder Valerie A, Wolter William R, Suckow Mark A, Mobashery Shahriar, Chang Mayland
机构信息
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Freimann Life Sciences Center and Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556, United States.
出版信息
ACS Med Chem Lett. 2019 Oct 3;11(3):322-326. doi: 10.1021/acsmedchemlett.9b00379. eCollection 2020 Mar 12.
Abstract
A structure-activity relationship (SAR) for the oxadiazole class of antibacterials was evaluated by syntheses of 72 analogs and determination of the minimal-inhibitory concentrations (MICs) against the ESKAPE panel of bacteria. Selected compounds were further evaluated for toxicity, plasma protein binding, pharmacokinetics (PK), and a mouse model of methicillin-resistant (MRSA) infection. Oxadiazole shows potent antibacterial activity, exhibits low clearance, a high volume of distribution, and 41% oral bioavailability, and shows efficacy in mouse models of MRSA infection.
摘要
通过合成72种类似物并测定对ESKAPE细菌组的最低抑菌浓度（MIC），评估了恶二唑类抗菌剂的构效关系（SAR）。对选定的化合物进一步评估其毒性、血浆蛋白结合率、药代动力学（PK）以及耐甲氧西林金黄色葡萄球菌（MRSA）感染的小鼠模型。恶二唑显示出强效抗菌活性，清除率低，分布容积高，口服生物利用度为41%，并在MRSA感染的小鼠模型中显示出疗效。
相似文献
1
Structure-Activity Relationship for the Oxadiazole Class of Antibacterials.恶二唑类抗菌药物的构效关系
ACS Med Chem Lett. 2019 Oct 3;11(3):322-326. doi: 10.1021/acsmedchemlett.9b00379. eCollection 2020 Mar 12.
2
Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.4(3H)-喹唑啉酮类抗菌剂的构效关系
J Med Chem. 2016 May 26;59(10):5011-21. doi: 10.1021/acs.jmedchem.6b00372. Epub 2016 May 5.
3
Structure-activity relationship for the oxadiazole class of antibiotics.恶二唑类抗生素的构效关系。
J Med Chem. 2015 Feb 12;58(3):1380-9. doi: 10.1021/jm501661f. Epub 2015 Jan 30.
4
Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).新型诺氟沙星-1,3,4-噁二唑杂合子的设计与合成及其作为抗耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌剂。
Eur J Pharm Sci. 2019 Aug 1;136:104966. doi: 10.1016/j.ejps.2019.104966. Epub 2019 Jun 21.
5
The oxadiazole antibacterials.恶二唑类抗菌剂。
Curr Opin Microbiol. 2016 Oct;33:13-17. doi: 10.1016/j.mib.2016.05.009. Epub 2016 May 27.
6
[The history of the development and changes of quinolone antibacterial agents].[喹诺酮类抗菌药物的发展与变迁史]
Yakushigaku Zasshi. 2003;38(2):161-79.
7
Exploration of the structure-activity relationship of 1,2,4-oxadiazole antibiotics.1,2,4-恶二唑类抗生素构效关系的探索
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4854-4857. doi: 10.1016/j.bmcl.2015.06.044. Epub 2015 Jun 18.
8
Potent in vitro methicillin-resistant Staphylococcus aureus activity of 2-(1H-indol-3-yl)quinoline derivatives.2-(1H-吲哚-3-基)喹啉衍生物对耐甲氧西林金黄色葡萄球菌具有强大的体外活性。
Bioorg Med Chem Lett. 2000 Dec 4;10(23):2675-8. doi: 10.1016/s0960-894x(00)00542-4.
9
Activities of Oxadiazole Antibacterials against Staphylococcus aureus and Other Gram-Positive Bacteria.恶二唑类抗菌剂对金黄色葡萄球菌和其他革兰氏阳性菌的活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00453-18. Print 2018 Aug.
10
The relationship between structure and in vitro antibacterial activity of selected isoflavones and their metabolites with special focus on antistaphylococcal effect of demethyltexasin.所选异黄酮及其代谢产物的结构与体外抗菌活性之间的关系，特别关注去甲基柚木苷元的抗葡萄球菌作用。
Lett Appl Microbiol. 2015 Mar;60(3):242-7. doi: 10.1111/lam.12361. Epub 2014 Dec 21.
引用本文的文献
1
A Potent and Narrow-Spectrum Antibacterial against Infection.一种强效且窄谱的抗菌药物，针对 感染。
J Med Chem. 2023 Oct 26;66(20):13891-13899. doi: 10.1021/acs.jmedchem.3c01249. Epub 2023 Sep 21.
2
Simple and Efficient Synthesis of Diamino Derivatives of bis-1,2,4-oxadiazole Tandem Staudinger/aza-Wittig Reaction.双-1,2,4-噁二唑的二氨基衍生物的简单高效合成 通过Staudinger/aza-Wittig 串联反应。
Curr Org Synth. 2023;20(6):589-594. doi: 10.2174/1570179420666221006113032.
3
Highly Active Small Aminated Quinolinequinones against Drug-Resistant and .高效小分子氨基喹啉醌类化合物抗耐药 和 。
Molecules. 2022 May 3;27(9):2923. doi: 10.3390/molecules27092923.
4
Mechanistic Studies and Efficacy of an Oxadiazole-Containing Antibiotic.含恶二唑的抗生素的作用机制研究及疗效
J Med Chem. 2022 May 12;65(9):6612-6630. doi: 10.1021/acs.jmedchem.1c02034. Epub 2022 Apr 28.
5
3D-QSAR Studies of 1,2,4-Oxadiazole Derivatives as Sortase A Inhibitors.3D-QSAR 研究 1,2,4-恶二唑衍生物作为 sortase A 抑制剂。
Biomed Res Int. 2021 Dec 6;2021:6380336. doi: 10.1155/2021/6380336. eCollection 2021.
6
Synergism of a Novel 1,2,4-oxadiazole-containing Derivative with Oxacillin against Methicillin-Resistant .一种含新型1,2,4-恶二唑的衍生物与苯唑西林对耐甲氧西林菌的协同作用
Antibiotics (Basel). 2021 Oct 16;10(10):1258. doi: 10.3390/antibiotics10101258.
7
π-π Noncovalent Interaction Involving 1,2,4- and 1,3,4-Oxadiazole Systems: The Combined Experimental, Theoretical, and Database Study.π-π 非共价相互作用涉及 1,2,4-和 1,3,4-恶二唑系统：综合实验、理论和数据库研究。
Molecules. 2021 Sep 18;26(18):5672. doi: 10.3390/molecules26185672.
8
Unconventional Antibacterials and Adjuvants.非传统抗菌药物和佐剂。
Acc Chem Res. 2021 Feb 16;54(4):917-929. doi: 10.1021/acs.accounts.0c00776. Epub 2021 Jan 29.
9
Physicochemical and Structural Parameters Contributing to the Antibacterial Activity and Efflux Susceptibility of Small-Molecule Inhibitors of Escherichia coli.对大肠杆菌小分子抑制剂的抗菌活性和外排易感性有贡献的物理化学和结构参数。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01925-20.
10
β-Lactams against the Fortress of the Gram-Positive Bacterium.β-内酰胺类药物对抗革兰阳性菌的堡垒。
Chem Rev. 2021 Mar 24;121(6):3412-3463. doi: 10.1021/acs.chemrev.0c01010. Epub 2020 Dec 29.
本文引用的文献
1
In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.恶二唑类抗菌剂与β-内酰胺类药物的体外和体内协同作用
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5581-8. doi: 10.1128/AAC.00787-16. Print 2016 Sep.
2
Structure-activity relationship for the oxadiazole class of antibiotics.恶二唑类抗生素的构效关系。
J Med Chem. 2015 Feb 12;58(3):1380-9. doi: 10.1021/jm501661f. Epub 2015 Jan 30.
3
Update on the antibiotic resistance crisis.抗生素耐药性危机的最新情况。
Curr Opin Pharmacol. 2014 Oct;18:56-60. doi: 10.1016/j.coph.2014.09.006. Epub 2014 Sep 23.
4
Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity.发现一类具有革兰氏阳性抗菌活性的新型青霉素结合蛋白非β-内酰胺抑制剂。
J Am Chem Soc. 2014 Mar 5;136(9):3664-72. doi: 10.1021/ja500053x. Epub 2014 Feb 21.
5
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.有害病菌，无药可医：谨防“ESKAPE”！美国传染病学会的最新报告
Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.
6
Impact of pH on plasma protein binding in equilibrium dialysis.pH对平衡透析中血浆蛋白结合的影响。
Mol Pharm. 2008 May-Jun;5(3):438-48. doi: 10.1021/mp800004s. Epub 2008 Mar 18.
7
Predicting plasma protein binding of drugs: a new approach.预测药物的血浆蛋白结合：一种新方法。
Biochem Pharmacol. 2002 Nov 1;64(9):1355-74. doi: 10.1016/s0006-2952(02)01074-2.
8
Protein binding and serum bactericidal activities of vancomycin and teicoplanin.万古霉素和替考拉宁的蛋白结合及血清杀菌活性
Antimicrob Agents Chemother. 1995 Aug;39(8):1842-7. doi: 10.1128/AAC.39.8.1842.
9
Effect of protein binding of daptomycin on MIC and antibacterial activity.达托霉素的蛋白结合对最低抑菌浓度及抗菌活性的影响。
Antimicrob Agents Chemother. 1991 Dec;35(12):2505-8. doi: 10.1128/AAC.35.12.2505.
Zotero 插件